{"links":{"html":"https://www.erudio.com/reports/origami-1-nct05379595","json":"https://www.erudio.com/reports/origami-1-nct05379595.json","markdown":"https://www.erudio.com/reports/origami-1-nct05379595.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"origami-1-05379595"}},"request":"https://www.erudio.com/contact?report=origami-1-05379595"},"offer":{"cited_commentary_sources":33,"verified_hcp_statements":180,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":18,"optional":true,"price_per_verified_person_usd":15,"price_usd":270,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"origami-1-nct05379595"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=origami-1-05379595","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/origami-1-nct05379595","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_rule":"Standard: 151–300 verified statements","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T16:21:33.027629Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":16,"no_commentary_found":7},"aspects":[{"claim_count":16,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":11,"title":"Primary endpoint: Cohorts A, B, and C: Objective Response Rate (ORR)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: Cohorts Ph1b-D and Ph1b-E: Number of Participants with Dose-limiting Toxicity (DLT)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":0,"title":"Primary endpoint: Cohorts Ph1b-D and Ph1b-E: Number of Participants with DLT by Severity"},{"claim_count":3,"coverage":"discussed","id":"T4","registry_field":"outcomesModule.primaryOutcomes[3]","source_count":3,"title":"Primary endpoint: Cohorts D and E: Number of Participants with Adverse Events (AE)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"outcomesModule.primaryOutcomes[4]","source_count":0,"title":"Primary endpoint: Cohorts D and E: Number of Participants with Laboratory Values Abnormalities"},{"claim_count":0,"coverage":"no_commentary_found","id":"T6","registry_field":"outcomesModule.primaryOutcomes[5]","source_count":0,"title":"Primary endpoint: Cohorts D and E: Number of Participants with Vital Signs Abnormalities"},{"claim_count":0,"coverage":"no_commentary_found","id":"T7","registry_field":"outcomesModule.primaryOutcomes[6]","source_count":0,"title":"Primary endpoint: Cohorts F: Number of Participants with Adverse Events (AE)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T8","registry_field":"outcomesModule.primaryOutcomes[7]","source_count":0,"title":"Primary endpoint: Cohorts F: Number of Participants with Laboratory Values Abnormalities"},{"claim_count":0,"coverage":"no_commentary_found","id":"T9","registry_field":"outcomesModule.primaryOutcomes[8]","source_count":0,"title":"Primary endpoint: Cohorts F: Number of Participants with Vital Signs Abnormalities"},{"claim_count":14,"coverage":"discussed","id":"T10","registry_field":"outcomesModule.secondaryOutcomes","source_count":11,"title":"Secondary endpoints"},{"claim_count":13,"coverage":"discussed","id":"T11","registry_field":"conditionsModule","source_count":9,"title":"Population and setting"},{"claim_count":7,"coverage":"discussed","id":"T12","registry_field":"armsInterventionsModule.armGroups","source_count":7,"title":"The comparison"},{"claim_count":12,"coverage":"discussed","id":"T13","registry_field":"outcomesModule","source_count":11,"title":"Safety and tolerability"},{"claim_count":12,"coverage":"discussed","id":"T14","registry_field":"designModule","source_count":7,"title":"Design and conduct"},{"claim_count":8,"coverage":"discussed","id":"A1","source_count":1,"title":"Right-sided second-line trial consideration and reasons for caution"},{"claim_count":12,"coverage":"discussed","id":"A2","source_count":5,"title":"EGFR rechallenge biology, interval and intervening treatment"},{"claim_count":8,"coverage":"discussed","id":"A3","source_count":1,"title":"ctDNA implementation, funding and unequal access"},{"claim_count":22,"coverage":"discussed","id":"A4","source_count":3,"title":"Conventional anti-EGFR alternatives, sidedness and molecular work-up"},{"claim_count":18,"coverage":"discussed","id":"A5","source_count":7,"title":"Resistance mechanisms and exploratory correlative markers"},{"claim_count":29,"coverage":"discussed","id":"A6","source_count":16,"title":"Earlier-line combination development and randomized comparator questions"},{"claim_count":9,"coverage":"discussed","id":"A7","source_count":1,"title":"Alternative bispecific strategies and preserving useful chemotherapy"},{"claim_count":2,"coverage":"discussed","id":"A8","source_count":1,"title":"Subcutaneous formulation in the CRC setting"},{"claim_count":13,"coverage":"discussed","id":"A9","source_count":9,"title":"Access seeking, public amplification and patient-facing participation descriptions"}],"counts":{"cited_sources":34,"claims_by_expression_type":{"comparison":11,"experience":8,"interpretation":63,"opinion":29,"primary_context":6,"question":7,"restatement":37,"uncertainty":6,"unspecified":13},"claims_by_kind":{"objective_result":2,"protocol_statement":1,"publication_statement":20,"source_observation":157},"clinician_statements":102,"evidence_units":125,"findings":11,"organisational_accounts":7,"people_cited":23,"people_identity_verified":18,"people_total":23,"screened_sources":70,"verified_claims":180},"findings_index":[{"id":"F1","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":1,"questions":1,"restated":1,"views":4},"has_counterview":true,"limitations":2,"links":{"context":4,"support":8},"ma_question":true,"named_voices":3,"passages":6,"sources":1,"sources_by_kind":{"media":1}},"title":"Right-sided activity supports a trial discussion, not an unconditional treatment recommendation"},{"id":"F2","structure":{"claims":18,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":5,"views":10},"has_counterview":true,"limitations":3,"links":{"context":3,"support":21},"ma_question":true,"named_voices":6,"passages":16,"sources":7,"sources_by_kind":{"commentary":3,"media":3,"publication":1}},"title":"Activity after anti-EGFR exposure and in right-sided disease drives enthusiasm, with important evidence limits"},{"id":"F3","structure":{"claims":14,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":3,"views":9},"has_counterview":true,"limitations":3,"links":{"context":0,"support":16},"ma_question":true,"named_voices":4,"passages":9,"sources":6,"sources_by_kind":{"commentary":4,"media":1,"publication":1}},"title":"Rechallenge interest depends on interval, prior response and molecular reversion—not elapsed time alone"},{"id":"F4","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":1,"questions":2,"restated":0,"views":5},"has_counterview":false,"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":1,"passages":2,"sources":1,"sources_by_kind":{"media":1}},"title":"ctDNA-guided selection is constrained by access to both testing and treatment"},{"id":"F5","structure":{"claims":23,"claims_by_group":{"comparisons":1,"experience":4,"questions":1,"restated":5,"views":12},"has_counterview":true,"limitations":3,"links":{"context":4,"support":27},"ma_question":true,"named_voices":4,"passages":16,"sources":3,"sources_by_kind":{"media":3}},"title":"Molecular characterization may refine sidedness-based selection, but does not erase treatment-line distinctions"},{"id":"F6","structure":{"claims":19,"claims_by_group":{"comparisons":2,"experience":0,"questions":3,"restated":3,"views":11},"has_counterview":true,"limitations":3,"links":{"context":3,"support":22},"ma_question":true,"named_voices":5,"passages":16,"sources":8,"sources_by_kind":{"media":7,"publication":1}},"title":"Mechanistic and correlative interest remains hypothesis-led"},{"id":"F7","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":2,"views":7},"has_counterview":true,"limitations":3,"links":{"context":0,"support":12},"ma_question":true,"named_voices":8,"passages":11,"sources":9,"sources_by_kind":{"commentary":7,"media":1,"publication":1}},"title":"Manageable toxicity is not negligible toxicity, and the formulation question remains setting-specific"},{"id":"F8","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":1,"views":5},"has_counterview":true,"limitations":4,"links":{"context":1,"support":8},"ma_question":true,"named_voices":7,"passages":8,"sources":6,"sources_by_kind":{"commentary":6}},"title":"Earlier-line combination signals generate interest without establishing chemotherapy replacement"},{"id":"F9","structure":{"claims":22,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":14,"views":7},"has_counterview":true,"limitations":4,"links":{"context":4,"support":29},"ma_question":true,"named_voices":7,"passages":15,"sources":10,"sources_by_kind":{"commentary":3,"media":7}},"title":"Phase 3 development is anticipated validation, not validation already achieved"},{"id":"F10","structure":{"claims":10,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":3,"views":5},"has_counterview":true,"limitations":3,"links":{"context":1,"support":11},"ma_question":true,"named_voices":2,"passages":9,"sources":1,"sources_by_kind":{"media":1}},"title":"Alternative bispecifics broaden the development question, with tolerability and small datasets limiting comparison"},{"id":"F11","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":2,"questions":0,"restated":1,"views":6},"has_counterview":false,"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":7,"passages":8,"sources":8,"sources_by_kind":{"commentary":8}},"title":"Strong public reactions and compassionate-use applications do not establish treatment delivery or consensus"}],"medical_affairs_question":"What comparative benefit, molecular selection, treatment-free interval, tolerability and feasible access pathway would justify moving from trial interest to a routine-care role?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Right-sided disease: preserve the enrollment conditions"},{"id":"section-2","level":2,"title":"Activity and durability: enthusiasm without established comparative benefit"},{"id":"section-3","level":2,"title":"Rechallenge: separate biological eligibility from interval associations"},{"id":"section-4","level":2,"title":"ctDNA implementation: eligibility is useful only if a pathway exists"},{"id":"section-5","level":2,"title":"Selection beyond sidedness: molecular features, line and timing"},{"id":"section-6","level":2,"title":"Mechanism and biomarkers: reasons for interest, not clinical selection rules"},{"id":"section-7","level":2,"title":"Safety and formulation: distinguish discontinuation from burden"},{"id":"section-8","level":2,"title":"Earlier-line combinations: incremental value, not chemotherapy replacement"},{"id":"section-9","level":2,"title":"Randomized development: comparisons still to answer"},{"id":"section-10","level":2,"title":"Alternatives and the value of retaining chemotherapy"},{"id":"section-11","level":2,"title":"Public enthusiasm, access seeking and participation information"},{"id":"section-12","level":2,"title":"Scope and coverage"},{"id":"section-13","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, parallel, phase1, phase2","trial_dimensions":[{"findings":[{"id":"F2","shared_claims":5},{"id":"F7","shared_claims":4},{"id":"F11","shared_claims":1}],"id":"T1","label":"Primary endpoint: Cohorts A, B, and C: Objective Response Rate (ORR)"},{"findings":[],"id":"T2","label":"Primary endpoint: Cohorts Ph1b-D and Ph1b-E: Number of Participants with Dose-limiting Toxicity (DLT)"},{"findings":[],"id":"T3","label":"Primary endpoint: Cohorts Ph1b-D and Ph1b-E: Number of Participants with DLT by Severity"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F7","shared_claims":1},{"id":"F8","shared_claims":2}],"id":"T4","label":"Primary endpoint: Cohorts D and E: Number of Participants with Adverse Events (AE)"},{"findings":[],"id":"T5","label":"Primary endpoint: Cohorts D and E: Number of Participants with Laboratory Values Abnormalities"},{"findings":[],"id":"T6","label":"Primary endpoint: Cohorts D and E: Number of Participants with Vital Signs Abnormalities"},{"findings":[],"id":"T7","label":"Primary endpoint: Cohorts F: Number of Participants with Adverse Events (AE)"},{"findings":[],"id":"T8","label":"Primary endpoint: Cohorts F: Number of Participants with Laboratory Values Abnormalities"},{"findings":[],"id":"T9","label":"Primary endpoint: Cohorts F: Number of Participants with Vital Signs Abnormalities"},{"findings":[{"id":"F2","shared_claims":4},{"id":"F7","shared_claims":6},{"id":"F8","shared_claims":3}],"id":"T10","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F7","shared_claims":1},{"id":"F9","shared_claims":1}],"id":"T11","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F8","shared_claims":2},{"id":"F9","shared_claims":1}],"id":"T12","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":3},{"id":"F7","shared_claims":8},{"id":"F8","shared_claims":2},{"id":"F10","shared_claims":1}],"id":"T13","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":4},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":2},{"id":"F9","shared_claims":6},{"id":"F10","shared_claims":1}],"id":"T14","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T16:21:33.027629Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T16:33:33Z","record_hash":"a6af51d4541059e0304bb42d2f5d8ed3ad11bffc9788bcc91f89e770d8be18f5","release_hash":"e9c692bac11f927dc671a72d418081f57411561a0bc003fe259b9757a302a051","report_id":"erudio-nct05379595","run_id":"01393e57-6727-42ef-8d0f-618cc032242e","schema_version":"5.0","slug":"origami-1-05379595","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"OrigAMI-1 asks whether amivantamab, alone or with chemotherapy, can produce tumor responses with acceptable safety in advanced or metastatic colorectal cancer. Commentary spans X and Bluesky posts, podcasts and YouTube discussions, with medical oncologists among the speakers. The discussion turns on how far enthusiasm for amivantamab in right-sided or previously anti-EGFR-treated disease should extend, when EGFR-directed rechallenge is appropriate, and whether earlier-line chemotherapy combinations will gain phase 3 validation.","meta_description":"70 sources screened · 180 verified statements (102 from clinicians verified by NPI or staff page) from 34 sources · 11 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-61bcc5b63493bfb44520","claim-9e93ab54480429b52025"],"id":"F8","paraphrase":"An X reply asked whether chemotherapy with bevacizumab should be the comparator in a larger study of amivantamab plus chemotherapy.","publication_caveats":{"reason":"Publication caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"x_thread","source_date":"2024-09-14","title":"Earlier-line combination signals generate interest without establishing chemotherapy replacement"},{"cited_claim_ids":["claim-2890dea4e94f35b5d479"],"id":"F9","paraphrase":"A medical oncologist in a YouTube discussion asked which patients were eligible for OrigAMI-1.","publication_caveats":{"reason":"Publication caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"youtube","source_date":"2026-05-29","title":"Phase 3 development is anticipated validation, not validation already achieved"}]},"publication":{"approved_at":"2026-10-31T16:33:33Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":70},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on pembrolizumab versus chemotherapy and crossover-related interpretation in MSI-high advanced or metastatic colorectal cancer.","Not yet captured in this edition: a view on orthogonal confirmation of mismatch-repair testing to avoid misclassification before metastatic colorectal cancer treatment.","Not yet captured in this edition: a view on alternative later-line treatment sequences guided by patient goals and discussion of risks and benefits.","Not yet captured in this edition: a view on dual-method mismatch-repair testing to avoid misclassification when selecting treatment for metastatic colorectal cancer.","Not yet captured in this edition: a view on confirming mismatch-repair immunohistochemistry with an orthogonal method to avoid misclassification before systemic-treatment selection.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","178 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","Discussion coverage is incomplete. References that do not use the trial's recognized names or identifier, including different spellings, may be missing.","Some portions of longer discussions were not fully assessed for clinician views; potentially relevant testing and treatment-sequencing positions may therefore be absent. The referral discussion is not exhaustive: not every alternative trial and its prior-treatment conditions is described here.","Multiple podcast/video versions and reposts repeat material. Source counts cannot be interpreted as independent-HCP counts or consensus.","Some remarks cannot be assigned to a named speaker. A participant list, title, profile or publication authorship does not resolve who spoke those passages.","Some named public authors do not have an established clinical role in the sources reviewed. Organizational summaries and source-described roles or trial involvement are not independent confirmation of clinical credentials or independence.","The early-phase monotherapy population was highly selected, with small cohorts, early enrollment closure in two cohorts and possible survivor bias in the interval analysis. These constraints limit generalization and comparative interpretation.","Different reports concern monotherapy, chemotherapy combinations, different cohorts and different follow-up. Their response, durability and safety descriptions should not be pooled.","A speaker's right-sided CRC post and another speaker's future-studies interview do not name OrigAMI-1 and are treated as setting or development context, not as this trial's results.","Some source descriptions of treatment allocation, comparators and eligibility are not corroborated by the cited primary statements. They are preserved as what was said, not as validated study methods.","A full protocol and complete colorectal-cancer regulatory assessment were not available. This report does not establish exact current eligibility, entitlement to access or approved CRC use."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":3,"publication":1,"registry":0,"regulatory":0,"x_thread":22,"x_video":0,"youtube":8},"by_evidence_role":{"commentary":33,"results":1},"count":34,"evidence_window":{"end":"2026-08-13","start":"2023-09-15"},"retrieval_snapshot":"2026-10-31T14:01:56.938600Z","timeline":[{"count":1,"week":"2023-W37"},{"count":1,"week":"2024-W37"},{"count":1,"week":"2024-W39"},{"count":1,"week":"2025-W04"},{"count":2,"week":"2025-W05"},{"count":1,"week":"2025-W26"},{"count":1,"week":"2025-W29"},{"count":1,"week":"2025-W31"},{"count":1,"week":"2026-W02"},{"count":2,"week":"2026-W03"},{"count":1,"week":"2026-W07"},{"count":8,"week":"2026-W17"},{"count":2,"week":"2026-W18"},{"count":1,"week":"2026-W22"},{"count":2,"week":"2026-W23"},{"count":1,"week":"2026-W24"},{"count":1,"week":"2026-W27"},{"count":2,"week":"2026-W28"},{"count":2,"week":"2026-W31"},{"count":1,"week":"2026-W33"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT05379595:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05379595:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:42013403","quote_policy":"no_derivatives"},{"id":"openfda:f0b60247-89ff-42b5-a55b-61980c282749:20260814","quote_policy":"short_quote_link_out"},{"id":"openfda:f7004cbd-9827-466e-9683-adce4f13c6a6:20260701","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-h5urapbydiprqb4y24ke2utc-3lgca2fyeh22i","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-km6ed4kyyj5hkysfzffqm3vw-3mldrygbsum2u","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-tsqfr6zfxr7jcxoceowmozu4-3msbvqrbwf42x","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3mkawm6mba42z","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:337e7f","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:6949bb","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:7b7ee3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1676656016966950930:12dbade0-038e-46ff-b221-c59658a36ed9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834957804529946849:c94bd306-8ff8-4696-a3e1-fc7256ab4fad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834959160946864238:67c3267b-e743-4ad5-b5b0-a1c082713dec","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834963001817870764:2be13491-82f0-4216-a7b6-258eecbdc0c8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834963565645615495:48d78492-4886-4074-a9ea-fc83d95c08b7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834966160246280300:638c39d3-168d-499e-ad12-5832f1d045cd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835020826040574420:20088e63-9029-4ef4-883f-5708c7fd3c42","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1839674312682266798:9c09de55-59c1-4484-88a8-82a159be4600","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1840051339646128193:26adc300-5c1b-4666-8b48-14f0d941bfd1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1872781761522139286:5cd5e5c3-d1d8-4978-9832-8aac6ae30aa4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1881875618037661796:b57ae530-217e-4bca-80cd-e47d9b7c951b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1881919703020372077:04d56ac4-1c7f-4afb-8533-f6af62d47bea","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1883276214426653061:c56f007c-b512-4648-99e4-800e0da9ef81","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1884723507340173328:3976b00e-91e1-49a4-9663-44645ee32e9f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1887124016197980336:8bf04587-3994-4538-93bc-45d275d07791","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928859964690330087:1b443cf4-051e-417f-a052-a73d9dacec73","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1940494794607714564:cea0b68a-f6c2-48ee-b207-408d2f92946b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1945858005423300825:407d07a0-e074-4eb6-8114-3ffcd4f4e0f8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1946473698665320741:8ff91802-bf8e-40f2-952e-b7064b1fc461","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1950194685114237376:5837c9a7-2dab-49d0-b001-55c5c8d5194e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2010015354463105538:10bba47d-d3b0-4bb4-b9d0-6a0754f2f930","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2010143914506981745:911e03f6-c5b8-47f9-89fd-3f409ac723f4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2010691668949807416:0a455184-46c6-4293-ae7a-df3a3974a69c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2011110134743785564:70896434-98c9-401e-8818-9712c447d7b9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2011136160093905376:c273193d-bd1c-4525-941a-48b69c2738ab","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2011205050623017045:abc36852-4253-4f3e-ad78-ddec8c8ee817","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2014089310421590514:deea9846-dfc5-49b8-81c2-1cff3d1cf565","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2016257402912288901:187f7c4b-4e00-49b3-a715-f5d61830c326","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2016938136337527290:2160b6f8-81c0-4795-8c2c-4b2df627cc3a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2029488392606499137:130f6bbd-3324-480f-bfa6-2955a3c865b3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2046770494331027520:90d09fa7-fc05-42a9-b471-a827133c57b6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2046869997314527317:489593ca-c2ac-4109-b9c8-ec513aa421fc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047023274304139315:494f9a62-1045-4dbc-b308-a25da607d33f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047095017605366159:da4a62fe-0f6a-45a6-93fe-977f1941f403","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047200856244715851:16d4a8f5-1aa6-438c-9281-5a925fc13954","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047226356048568477:6c29675f-dd94-4e02-8263-b8d954ad9762","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047320314410156166:e0fa461b-822d-4c18-a1ef-2747e3ac6937","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047511262565724173:08f741f2-5717-458c-b7e6-2da7e7cd2522","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047712263612633467:ed20350a-44b7-4fd9-bdba-e8c24c88cfd8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047716644890333617:102d05cd-c0c9-459e-8fcb-bcaedbc9012e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047809942480945346:95fb0b40-d2d2-4f10-afe2-9b6e2f313508","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2048767068796043622:fa13734b-a4bc-4a44-90cc-fff8ea43cd62","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2049094208938709049:e6f2fe44-9447-4a3f-bb98-d45f917d8686","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050234848644657550:d1e92828-2fc8-4bb7-af1f-d878682363dd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050576344560324707:650fff7c-f05f-42f6-8350-3e91514c152e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2054954978477813859:676032b0-a14a-4160-8024-4f090d4dc92d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2059906851580342737:9eb97fa1-c128-4d71-8995-1fe8afefe873","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2062538956823011376:73069098-0716-4756-aa90-d6f18cd004be","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065885277684416706:c7c09b30-af5b-4794-ba3d-5ff728945f53","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2074210361973104753:d58e29ed-7d51-471b-ba9d-baab11009587","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2074575048740831740:c0431b5e-e9d4-452d-8c21-adee45083a87","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2088023783495860649:874eec11-d601-408c-9bb6-6ccdb61795a9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100955753263792524:0d1e838f-1c75-4c7a-9034-5d9bf3d81d30","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100957653392564335:fd1f4a03-2923-40a3-8f98-7227ecda790b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100967793273479499:8d6c7b6e-1dcc-4c97-94b3-f0056711caf2","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:0j-fYKNUmYs","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:5TH-QyDmHmc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:QALWmfdE7VQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:R0rexaM5ZCk","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:SrJI6cv4e6w","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Ul28psQyIEc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:gFWWXedsS8A","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:mQR1x_lYPm4","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":4,"linkedin_post":0,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":55,"x_video":0,"youtube":8},"by_evidence_role":{"commentary":70},"count":70,"evidence_window":{"end":"2026-09-18","start":"2023-07-05"},"retrieval_snapshot":"2026-10-31T14:01:56.938600Z","timeline":[{"count":1,"week":"2023-W27"},{"count":1,"week":"2023-W37"},{"count":6,"week":"2024-W37"},{"count":2,"week":"2024-W39"},{"count":1,"week":"2024-W44"},{"count":1,"week":"2024-W52"},{"count":4,"week":"2025-W04"},{"count":3,"week":"2025-W05"},{"count":1,"week":"2025-W06"},{"count":1,"week":"2025-W22"},{"count":1,"week":"2025-W26"},{"count":1,"week":"2025-W27"},{"count":2,"week":"2025-W29"},{"count":1,"week":"2025-W31"},{"count":2,"week":"2026-W02"},{"count":4,"week":"2026-W03"},{"count":1,"week":"2026-W04"},{"count":2,"week":"2026-W05"},{"count":1,"week":"2026-W07"},{"count":1,"week":"2026-W10"},{"count":12,"week":"2026-W17"},{"count":4,"week":"2026-W18"},{"count":1,"week":"2026-W19"},{"count":1,"week":"2026-W20"},{"count":2,"week":"2026-W22"},{"count":2,"week":"2026-W23"},{"count":1,"week":"2026-W24"},{"count":1,"week":"2026-W27"},{"count":3,"week":"2026-W28"},{"count":2,"week":"2026-W31"},{"count":1,"week":"2026-W32"},{"count":1,"week":"2026-W33"},{"count":3,"week":"2026-W38"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: amivantamab iv","status":"unmapped"},{"brand_names":["Adrucil","Favlyxa"],"label":"fluorouracil","slug":"fluorouracil"},{"brand_names":["Vykoura","Wellcovorin"],"label":"leucovorin","slug":"leucovorin"},{"brand_names":["Eloxatin"],"label":"oxaliplatin","slug":"oxaliplatin"},{"brand_names":["Camptosar"],"label":"irinotecan","slug":"irinotecan"},{"brand_names":["Rybrevant"],"label":"amivantamab","slug":"amivantamab"}],"indications":[{"reason":"Unmapped registry condition: Advanced or Metastatic Colorectal Cancer","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"OrigAMI-1","aliases":["OrigAMI-1","A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer"],"brief_title":"A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Advanced or Metastatic Colorectal Cancer"],"display_condition":"RAS/BRAF wild-type metastatic colorectal cancer","display_interventions":[["amivantamab"],["amivantamab","mFOLFOX6"],["amivantamab","FOLFIRI"]],"enrollment":{"count":225,"type":"ESTIMATED"},"interventions":[{"name":"Amivantamab IV","synonyms":["RYBREVANT","JNJ-61186372"],"type":"BIOLOGICAL"},{"name":"Fluorouracil","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"BIOLOGICAL"},{"name":"Leucovorin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"BIOLOGICAL"},{"name":"Oxaliplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"BIOLOGICAL"},{"name":"Irinotecan","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"BIOLOGICAL"},{"name":"Amivantamab","synonyms":["JNJ-61186372","RYBREVANT"],"type":"BIOLOGICAL"}],"nct_id":"NCT05379595","official_title":"A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","overall_status":"RECRUITING","phase":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-04-27","type":"ESTIMATED"},"primary_endpoints":[{"description":"ORR is defined as the percentage of participants who achieve either a partial response (PR) or complete response (CR), as defined by investigator assessment using Response Criteria in Solid Tumors (RECIST) version 1.1.","measure":"Cohorts A, B, and C: Objective Response Rate (ORR)","timeFrame":"Up to 4 years 3 months"},{"description":"Number of participants with DLT will be assessed. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.","measure":"Cohorts Ph1b-D and Ph1b-E: Number of Participants with Dose-limiting Toxicity (DLT)","timeFrame":"Up to 4 years 3 months"},{"description":"Number of participants with DLT by severity will be assessed. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity. Toxicities will be graded for severity according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0, graded as Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening, and Grade 5: death related to adverse event.","measure":"Cohorts Ph1b-D and Ph1b-E: Number of Participants with DLT by Severity","timeFrame":"Up to 4 years 3 months"},{"description":"An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. Severity of AEs will be graded according to the NCI CTCAE version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening and Grade 5: death related to adverse event.","measure":"Cohorts D and E: Number of Participants with Adverse Events (AE)","timeFrame":"Up to 4 years 3 months"},{"description":"Number of participants with laboratory values abnormalities, which includes serum chemistry, hematology, coagulation, and urinalysis, will be reported.","measure":"Cohorts D and E: Number of Participants with Laboratory Values Abnormalities","timeFrame":"Up to 4 years 3 months"},{"description":"Number of participants with vital signs including temperature, heart rate, respiratory rate, and blood pressure (systolic and diastolic) and oxygen saturation, abnormalities will be reported.","measure":"Cohorts D and E: Number of Participants with Vital Signs Abnormalities","timeFrame":"Up to 4 years 3 months"},{"description":"An AE is any untoward medical occurrence in a participant taking part in a in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. Severity of AEs will be graded according to the NCI-CTCAE version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening and Grade 5: death related to adverse event.","measure":"Cohorts F: Number of Participants with Adverse Events (AE)","timeFrame":"Up to 4 years 3 months"},{"description":"Number of participants with laboratory values abnormalities, which includes serum chemistry, hematology, coagulation, and urinalysis, will be reported.","measure":"Cohorts F: Number of Participants with Laboratory Values Abnormalities","timeFrame":"Up to 4 years 3 months"},{"description":"Number of participants with vital signs including temperature, heart rate, respiratory rate, and blood pressure (systolic and diastolic) and oxygen saturation, abnormalities will be reported.","measure":"Cohorts F: Number of Participants with Vital Signs Abnormalities","timeFrame":"Up to 4 years 3 months"}],"registered_date":{"date":"2022-05-18","type":"ACTUAL"},"registry_last_updated":"2026-09-25","registry_url":"https://clinicaltrials.gov/study/NCT05379595","short_name":"OrigAMI-1","short_name_basis":"registry_acronym","sponsor":"Janssen Research & Development, LLC","start_date":{"date":"2022-07-29","type":"ACTUAL"},"study_design":"interventional, non randomized, parallel, phase1, phase2","study_ids":[{"id":"CR109215","type":"sponsor_study_id"},{"domain":"Janssen Research & Development, LLC","id":"61186372GIC2002","type":"other"},{"id":"2021-006629-23","type":"eudract_number"},{"domain":"EUCT number","id":"2023-506517-22-00","type":"registry"}],"study_type":"INTERVENTIONAL"}}}